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Human immunodeficiency virus (HIV)
remains a significant public health chal-
lenge. According to the World Health
Organization, there were approximately
35.3 million people living with HIV/AIDS
worldwide in 2012, with Sub-Saharan
Africa being the most affected region (1).
HIV has claimed 27 million lives. It is esti-
mated that two million people die from
HIV/AIDS each year.
Highly active antiretroviral therapies
(HAART) now allow HIV-infected indi-
viduals to live longer and healthier lives.
HAART is, however, burdened with side
effects and high costs, and threatened
by evolving viral resistance. A hallmark
of both HIV and simian immunodefi-
ciency virus (SIV) infection is chronic
immune activation together with uncon-
trollable viremia and lymphocyte apoptosis
that progresses to acquired immunodefi-
ciency syndrome (AIDS) (2, 3). The dele-
terious role for immune activation in HIV
infection is supported by animal studies.
Although the exact mechanism underly-
ing AIDS resistance of natural hosts for
SIV, like sooty mangabey (SM) monkeys,
is unknown, reports support the idea that
disease progression in non-natural hosts
such as rhesus macaques (RM) is mainly
due to immune system dysfunction trig-
gered by HIV/SIV infections (4, 5). In
non-natural hosts, SIV causes progressive
impairment of the immune system char-
acterized by high viremia, CD4+ T cell
depletion, and loss of T cell function. Con-
tinuous CD4+ T cell loss eventually leads
to AIDS as the regenerative capacity of
the immune system gradually decreases
despite the excess of homeostatic cytokines
(6). This exhaustion and increased T cell
apoptosis, a phenomenon seen in path-
ogenic infections, may be due to direct
and indirect killing by the virus. Indirect-
or bystander-killing, is the loss of unin-
fected and abortively infected T cells possi-
bly due to generalized immune activation
(7, 8). It is widely accepted that type I
interferon-producing (IFN I) plasmacytoid
dendritic cells (pDC) play a central role in
this generalized immune activation (9–11).
On the other hand, natural simian hosts
preserve T lymphocyte populations despite
high viremia and show attenuated immune
activation that favors the maintenance of
CD4+ T cells; hence, SMs do not develop
AIDS (7). Although HIV preferentially
infects CD4+ T cells and macrophages,
efficient binding and infection of pDCs
by HIV have been demonstrated and may
contribute to AIDS pathogenesis (12, 13).
Plasmacytoid dendritic cells are special-
ized cells found in blood and lymphoid
tissues. The main function of pDCs is to
produce IFN in response to bacterial and
viral DNA. Following activation, these pro-
duce 1000-fold more IFN I than other
IFN producing cells (11). Upon HIV infec-
tion, pCDs become activated and express
CCR7 and CXCR3, migration markers that
induce redistribution to the lymph nodes
(LN) (14–16). Further, recent reports sug-
gest that HIV-induced pathogenesis occurs
mainly in LNs where the IFN I that pDCs
produce elevates serum levels during both
acute and chronic infections (13, 17–19).
Type I IFNs are powerful cytokines and
adaptive immune system modulators. They
are produced upon viral infection, replica-
tion, and/or the introduction of double-
stranded RNA (20). IFNs trigger antivi-
ral activity and induce the maturation
of effector T cells. Therefore, an inter-
esting immunoregulatory role for type I
IFN is in lymphocyte activation during
viral infection (21). There is, however, evi-
dence that this otherwise beneficial inter-
feron can become detrimental to the host
during chronic HIV infection. Persistent
levels of IFN I induce apoptosis in both
HIV-infected CD4+ T cells and in those
that do not become productively infected
(bystander-killing) leading to accelerated
depletion of CD4+ T cells during patho-
genic infection (22). This effect is due to
type I IFN triggered apoptosis of unin-
fected CD4+ T cells via TNF-related apop-
tosis inducing ligand (TRAIL) (17). Origi-
nally, SM, which are natural SIV hosts, were
thought to have reduced immune system
activation during both acute and chronic
SIV infections. Moreover, SM pDCs pro-
duce less IFN I ex vivo in response to
SIV, which leads to less immune activa-
tion during chronic infection (23). Other
works, however, have shown that natural
hosts exhibit an initially strong, but rapidly
controlled, IFN I response (24–26). There-
fore, both natural and non-natural hosts
mount strong type I IFN responses during
the acute stage of infection but only natural
hosts suppress the response by the chronic
stage, 4–16 months after infection. This
downregulation occurs despite sustained
high levels of viremia. Unlike natural hosts,
non-natural hosts maintain high levels of
IFN I production at all times. It is impor-
tant to note that cells from SIV-infected
natural hosts can be repeatedly stimulated
in vitro to produce type I IFN and to upreg-
ulate interferon-stimulated genes (ISG)
during the chronic stage of SIV infections
suggesting that these cells are neither more
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refractory nor resistant to re-stimulation
(26). Therefore, the downmodulation of
IFN I in natural hosts is likely due to nega-
tive control mechanisms. The exact mech-
anism underlying the downregulation of
IFN I is, however, not fully understood.
The regulatory complexity of the IFN path-
way and its overall effects on target cells
make pinpointing a resolution mechanism
challenging. A role for immunomodula-
tory proteins, negative regulation of IFN
responses, and other mechanisms have
been suggested [reviewed in Ref. (2)].
Efforts have been made to discover the IFN
I downregulation pathway by examining
the regulation of ISGs as well as immuno-
suppressive genes (24, 26). One common
denominator is the myxovirus resistance
protein (MxA or Mx1) gene. This finding
was supported by a recent clinical study in
which Chang et al. found that persistent
higher expression of type I IFN and ISGs,
including MxA, may explain, at least in
part, the increased immune activation and
more rapid disease progression in females
with chronic HIV infections when com-
pared to males with similar viral loads
(27). Harris et al. convincingly showed
that natural hosts African green monkeys
(AGM) and SM begin to downregulate
MxA responses by 28 dpi whereas non-
natural hosts (RM) maintained high levels
of MxA in LN. This work, however, did
not reveal a mechanism of IFN I resolution
(24). Further, it is unclear whether IFN is
directly downregulated or whether down-
stream signaling negatively regulates IFN.
Understanding the mechanism of Mx regu-
lation in the transition phase, from acute to
chronic infection of natural hosts, should
reveal new targets for therapies to block the
chronic immune system activation associ-
ated with disease progression.
MxA is an IFN induced protein
expressed in cells like macrophages and
hepatocytes. It is best known for its antivi-
ral activity against orthomyxoviruses (28).
MxA was first described in 1962 when Lin-
denmann showed that A2G inbred mice
were resistant to doses of mouse-adapted
influenza virus that were lethal to other
inbred mice. This resistance was dependent
on a single dominant locus named Mx1
and was exquisitely specific for orthomyx-
oviruses (29). Later, it was discovered that
Mx1 was the first member of a small
gene family and that the spectrum of
antiviral activity is in fact much larger
than originally thought. Most species have
one to three Mx protein isoforms with
different antiviral activity depending on
their intracellular localization (28). Mouse
Mx1 protein is found primarily in the
nucleus whereas human MxA is cytoplas-
mic. Hence, each protein blocks influenza
virus at a different stage of the viral
replication cycle (30). Of note, Mx2, an
interferon-induced protein, has recently
been shown to inhibit HIV infection after
entry (31, 32). Mx2, however, differs from
Mx1 in that Mx2 localizes to the nucleus
and its antiviral activity relies on a nuclear
localization signal (32).
What are Mx proteins and how do they
exert their antiviral activity? Most impor-
tantly, how are Mx proteins involved in
SIV/HIV infections? Mx proteins belong
to the superfamily of GTPases, which
includes dynamins, dynamin-like proteins,
and mitofusins [described in more detail
in Ref. (33)]. These proteins are involved
in endocytosis, intracellular vesicle trans-
port, and mitochondria distribution. Mx
proteins are mainly characterized by three
conserved domains: an N-terminal GTPase
domain (GTP binding), a middle domain
responsible for interaction with the GTPase
effector domain (GED), and the C-
terminus GED domain, which recognizes
the virus. Two amphipatic α-helices form
leucine zippers in the C-terminus. Further-
more, Mx proteins can self-assemble into
higher order ring-like structures to form a
helical stack (28). The higher order struc-
tures may represent a storage form whereas
the monomers are likely the active form of
MxA (34). Human MxA can be induced by
IFN or directly by the virus through dif-
ferent pathways. Activation of Mx by IFN
involves the Janus kinase/signal transducer
and activator of transcription (JAK/STAT)
pathway and the formation of an IFN-
stimulated gene factor 3 (ISGF3) multi-
meric complex, which in turn migrates into
the nucleus and binds an IFN-stimulated
response element (ISRE) upstream of the
Mx gene (35, 36). It is not yet clear how
viral infection activates Mx but it seems to
be independent of ISGF3, involving STAT1
instead and possibly the IFN-regulatory
factors 1 and 3 (IRF1 and IRF3) (37–39).
Mx gene activation is fast. Its protein prod-
uct is detectable within 4 h (40). It is thus
likely that Mx gene activation in response
to both virus and IFN through two different
pathways is evolutionarily advantageous to
the host. Indeed HIV can induce MxA tran-
scription and activate ISGs independently
of IFN (41). As mentioned previously, in
contrast to non-natural hosts, natural SIV
hosts downregulate MxA responses during
the transition to chronic infection despite
high viremia (24). Moreover with every
upregulation/activation, there must be a
downregulation of the response in order
to maintain homeostasis. Indeed overex-
pression of MxA is a common pathogenic
link in Fanconi Anemia (FA), which con-
sists of a group of at least five autosomal
recessive disorders. Overexpression of MxA
can lead to cancer susceptibility, apoptosis,
bone marrow failure, and abnormal insta-
bility in cells (42). One potential mech-
anism for regulation of Mx gene expres-
sion relies on the IRF-1 and IRF-2 pro-
teins. The most probable mediator of Mx
induction is IRF-1, which is increased in
the presence of virus and after IFN treat-
ment (43, 44). This suggests that the func-
tional synergy between the two indepen-
dent pathways converges in upregulation
of Mx. Additionally, the virus may syner-
gize with IFN to increase Mx levels. IRF-1
induces IRF-2 production to repress ISG
transcription. This in turn inhibits IRF-1
function. IRF-1 and IRF-2 share homology
in their DNA binding domain; however,
IRF-2 has higher affinity for binding and
a longer half-life (45). Interestingly, IRF-2
also protects quiescent hematopoietic stem
cells (HSC) from type I IFN exhaustion
(46). In order to avoid cancer suscepti-
bility, increased apoptosis, bone marrow
failure, and HSC depletion, natural SIV
hosts apparently evolved to control the IFN
responses (Figure 1); however, the exact
mechanism is not yet clear. Studying vari-
ations in the Mx genes, simultaneously
with standardized screening of their antivi-
ral properties in natural and non-natural
SIV hosts, could explain why natural hosts
can downregulate MxA responses with
the onset of the chronic stage of infec-
tion. Additionally, mining for polymor-
phisms in regulatory genes, such as IRF-2,
which correlate with enhanced DNA bind-
ing or half-life of the activated protein
may offer an avenue for designing new
therapeutics for controlling the immune
system hyperactivation that is associated
with AIDS progression.
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FIGURE 1 | Schematic of IFN and Mx protein regulation in acute and chronic SIV infection models.
CONCLUSION
Studies in non-human primates have
revealed the importance of immune acti-
vation in HIV/SIV pathogenesis. Chronic
immune activation, associated with CD4+
T cell depletion and loss of T cell function,
is likely due to increased serum levels of
type I IFN. Although type I IFN is necessary
to control viral infections, its detrimental
effects during the chronic stage of HIV/SIV
infection has been well documented. Nat-
ural SIV hosts, in sharp contrast to non-
natural SIV hosts, control IFN responses
with active regulatory mechanisms. Cur-
rently, it is not clear how this regulation
is achieved on the molecular level. Under-
standing the basis of active IFN response
repression is crucial as these may play an
important role in protection against dis-
ease progression. Regulation of the type
I IFN pathway is very complex making it
hard to narrow down the exact factor or
factors responsible for repression of this
pathway. Evidence supporting a role for
MxA genes, warrants studying polymor-
phisms in MxA genes, which may shed light
on the mechanism of active IFN downreg-
ulation. Additionally, better understanding
of how Mx genes are regulated will further
broaden our perspective for understanding
the evolution of host–virus interactions.
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